Patents by Inventor Cynthia Richard

Cynthia Richard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190169603
    Abstract: Provided herein are methods and compositions for labeling target nucleic acid molecules with molecular barcodes.
    Type: Application
    Filed: February 13, 2019
    Publication date: June 6, 2019
    Applicant: New England Biolabs, Inc.
    Inventors: Cynthia Richard, Brendan Galvin
  • Patent number: 10087481
    Abstract: Methods and compositions are provided for enriching for target sequences from a population of nucleic acids, that includes: combining in solution, a population of nucleic acids and a target isolation probe wherein the target isolation probe comprises an affinity binding domain; permitting a single stranded region of the target isolation probe to hybridize to all or a portion of a target sequence in the population of nucleic acids; selectively immobilizing the hybridized nucleic acids from the population containing the target sequences by associating the target isolation probe with a capture domain and removing unbound material; removing non-target sequences from the 3? end of the target sequence by means of one or more 3? exonucleases thereby generating a blunt ended duplex or a staggered end at the 3? end of the target sequence; optionally ligating a 3? duplex adaptor or a duplex end of a hairpin adaptor to the 3? end of the target sequence and the 5? end of the target isolation probe; extending the 3? end o
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: October 2, 2018
    Assignee: New England Biolabs, Inc.
    Inventor: Cynthia Richard
  • Publication number: 20150119261
    Abstract: Methods and compositions are provided for enriching for target sequences from a population of nucleic acids, that includes: combining in solution, a population of nucleic acids and a target isolation probe wherein the target isolation probe comprises an affinity binding domain; permitting a single stranded region of the target isolation probe to hybridize to all or a portion of a target sequence in the population of nucleic acids; selectively immobilizing the hybridized nucleic acids from the population containing the target sequences by associating the target isolation probe with a capture domain and removing unbound material; removing non-target sequences from the 3? end of the target sequence by means of one or more 3? exonucleases thereby generating a blunt ended duplex or a staggered end at the 3? end of the target sequence; optionally ligating a 3? duplex adaptor or a duplex end of a hairpin adaptor to the 3? end of the target sequence and the 5? end of the target isolation probe; extending the 3? end o
    Type: Application
    Filed: December 11, 2014
    Publication date: April 30, 2015
    Applicant: NEW ENGLAND BIOLABS, INC.
    Inventor: Cynthia Richard
  • Publication number: 20070088271
    Abstract: A dispenser for medicaments comprises a first metering pump for insulin and a second metering pump for glucose or glucagon. A controller for both pumps is programmed to maintain a basal supply of insulin, and is responsive to a signal from a separate glucometer to dispense additional insulin or glucose or glucagon as appropriate.
    Type: Application
    Filed: October 10, 2006
    Publication date: April 19, 2007
    Inventor: Cynthia Richards
  • Patent number: 6699690
    Abstract: Novel molecular chimaeras produced by recombinant DNA techniques are described. They comprise a target-tissue specific transcriptional regulatory sequence (TRS) linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase (VZV TK) or non-mammaliam Cytosine Deaminase (CD). A molecular chimaera is packaged into a synthetic retroviral particle that is capable of infecting mammalian tissue. This, in turn, may be administered to a host, and the TRS will be selectively transcriptionally activated in the target tissue (for example cancerous cells). Administration of compounds that are selectively metabolised by the enzyme produce cytotoxic or cytostatic metabolites in situ thereby selectively killing or arresting the growth of the target cells.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: March 2, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Brian Huber, Cynthia A. Richards
  • Publication number: 20020055482
    Abstract: Novel molecular chimaeras produced by recombinant DNA techniques are described. They comprise a target-tissue specific transcriptional regulatory sequence (TRS) linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase (VZV TK) or non-mammaliam Cytosine Deaminase (CD). A molecular chimaera is packaged into a synthetic retroviral particle that is capable of infecting mammalian tissue. This, in turn, may be administered to a host, and the TRS will be selectively transcriptionally activated in the target tissue (for example cancerous cells). Administration of compounds that are selectively metabolised by the enzyme produce cytotoxic or cytostatic metabolites in situ thereby selectively killing or arresting the growth of the target cells.
    Type: Application
    Filed: September 6, 2001
    Publication date: May 9, 2002
    Inventors: Brian Huber, Cynthia A. Richards, Elizabeth A. Austin
  • Patent number: 6337209
    Abstract: Novel molecular chimaeras produced by recombinant DNA techniques are described. They comprise a target-tissue specific transcriptional regulatory sequence (TRS) linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase (VZV TK) or non-mammaliam Cytosine Deaminase(CD). A molecular chimaera is packaged into a synthetic retroviral particle that is capable of infecting mammalian tissue. This, in turn, may be administered to a host, and the TRS will be selectively transcriptionally activated in the target tissue (for example cancerous cells). Administration of compounds that are selectively metabolised by the enzyme produce cytotoxic or cytostatic metabolites in situ thereby selectively killing or arresting the growth of the target cells.
    Type: Grant
    Filed: November 19, 1993
    Date of Patent: January 8, 2002
    Assignee: Glaxo Wellcome Inc.
    Inventors: Brian Huber, Cynthia A. Richards
  • Patent number: 6300490
    Abstract: Novel molecular chimaeras produced by recombinant DNA techniques are described. They comprise a target-tissue specific transcriptional regulatory sequence (TRS) linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase (VZV TK) or non-mammaliam Cytosine Deaminase(CD). A molecular chimaera is packaged into a synthetic retroviral particle that is capable of infecting mammalian tissue. This, in turn, may be administered to a host, and the TRS will be selectively transcriptionally activated in the target tissue (for example cancerous cells). Administration of compounds that are selectively metabolised by the enzyme produce cytotoxic or cytostatic metabolites in situ thereby selectively killing or arresting the growth of the target cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 9, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Brian Huber, Cynthia A. Richards, Elizabeth A. Austin